Blasts of a Different Sort
Can you tell what the diagnosis is for a man with a history of recurrent necrotizing pancreatitis and end-stage renal disease on intermittent hemodialysis by looking at his
Combining Daratumumab With Backbone Antimyeloma Agents
Dr. Raje reviews a study that compares daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone alone for the treatment of patients with multiple my
A concise review of a topic that illustrates the relationship of basic research to clinical hematology
Dr. Hoggatt discusses stem cell transplantation and looks at new, targeted conditioning approaches that have recently emerged, where the potential patient pool could be remarkably expanded with the advent of new gene therapy and editing strategies.
Dr. George and Dr. Czuchlewski cover the World Health Organization's 2016 updates to the classification of myeloid neoplasms.
Dr. Garcia highlights clinical recommendations from the ACCP's evidence-based guidelines for the treatment of venous thromboembolism (VTE) that are most relevant to hematologists.
Dr. Yang and Dr. Press evaluate the clinical utility of next-generation DNA sequencing (NGS) methods to profile the multiple actionable driver genes in patients with known and/or suspected myeloid malignancies.
Drs. Yao, Cardó-Vila, Ahmadian, Ebaid, Arap, and Pasqualini discuss the existence of tumor-specific molecular zip codes that can be used to design drugs to treat leukemia, lymphoma, and solid tumors.
Drs. Oh and Fisher discuss the application of mass cytometry to analyze disease evolution in hematologic malignancies.
Dr. Raje and Dr. Santo discuss new insights into MM-related bone biology and potential novel therapeutic approaches for treating bone disease.
Drs. Falet, Grozovsky, and Hoffmeister look at desialylated platelets to understand the steady state of hepatic TPO regulation and the mechanisms of thrombocytopenia observed in patients with MPNs treated with JAK1/2 inhibitors.
Dr. Cabantchik and Dr. Rachmilewitz talk about potential toxicity in Iron Overload Disorder caused by labile cell iron or labile iron pool.
To begin to define the regulation of native hematopoiesis, new work published by the Camargo laboratory describes clonal dynamics of hematopoiesis in mice using a novel cellular barcoding system.
January-February 2017Volume 14, Issue 1
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology